Kristi Savacool
About Kristi A. Savacool
Kristi A. Savacool, age 65, has served as an independent director of TrueBlue, Inc. since July 2018 (seven years of tenure). She is Chair of the Innovation & Technology Committee (since June 2022) and also serves on the Corporate Governance and Compensation Committees; her background includes serving as CEO of Aon Hewitt and CIO for Boeing Commercial Airplanes, bringing large-scale operations and HR outsourcing expertise to the board .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Aon Hewitt (Aon plc) | Chief Executive Officer | Not disclosed | Led global HR solutions business; professional services and outsourcing experience |
| The Boeing Company (Commercial Airplanes) | Chief Information Officer; senior executive roles in IT, operations, business services | Not disclosed | Large-scale, global operations; technology leadership |
External Roles
| Organization | Role | Type | Committees/Impact |
|---|---|---|---|
| Ascension Inc. | Director | Private | Not disclosed |
| RxBenefits, Inc. | Director | Private | Not disclosed |
| Escuela Adelante | Director | Nonprofit | Not disclosed |
| HealthQuest Capital | Board of Advisors | Nonprofit | Advisory role |
Board Governance
| Attribute | Detail |
|---|---|
| Independence | Independent director as determined March 27, 2025 |
| Years of Service | 7 years (director since July 2018) |
| Committee Assignments | Innovation & Technology (Chair), Corporate Governance, Compensation |
| Committee Meetings (2024) | Compensation: 5; Governance: 5; I&T: 4 |
| Attendance | All directors attended at least 75% of Board and committee meetings in 2024; Board met 7 times |
| Executive Sessions | Independent directors meet in executive session during Board/Governance meetings |
| Technology/Cyber Oversight | I&T Committee oversees technology strategy, cybersecurity, AI, data protection; all directors are members; Savacool is Chair |
| Conflicts Oversight | Governance Committee reviews conflicts and related party transactions |
| Related Party Transactions | None in 2024 |
Fixed Compensation (Director)
| Component | 2024 Amount | Notes |
|---|---|---|
| Board Cash Retainer | $77,000 | Non-employee director |
| Governance Committee Retainer | $5,000 | Member |
| Compensation Committee Retainer | $12,500 | Member |
| Innovation & Technology Committee Retainer | $5,000 | Member |
| Innovation & Technology Committee Chair Supplement | $15,000 | Chair |
| Total Cash Fees Earned | $114,500 | Matches director compensation table |
Performance Compensation (Director)
| Equity Element | Grant Basis / Date | Quantity / Value | Vesting |
|---|---|---|---|
| Annual RSU grant (Director) | Number determined from 60-day avg. price (~$14.18) as of second full trading day after Q4/year-end results; grant-date fair value uses closing price ($11.25) | Target value $135,000; as I&T Chair, additional RSUs $7,500; Savacool deferred 10,050 RSUs (100% of equity retainer) until 90 days post Board separation | 2024 RSUs vested on Sept 30, 2024; beginning 2025, RSUs vest on one-year anniversary of grant |
| Reported 2024 stock award (grant-date fair value) | 2024 | $113,063 (grant-date fair value) | Per FASB ASC 718 |
No director performance metrics (e.g., EBITDA/TSR) tied to director equity are disclosed; director equity is time-based RSUs with optional deferral elections .
Other Directorships & Interlocks
| External Board | Potential Interlock with TBI | Notes |
|---|---|---|
| Ascension Inc. (private) | None disclosed | Healthcare system; no disclosed TBI transactions |
| RxBenefits, Inc. (private) | None disclosed | Pharmacy benefits; no disclosed TBI transactions |
| Escuela Adelante (nonprofit) | N/A | Nonprofit |
| HealthQuest Capital Advisory Board (nonprofit) | N/A | Advisory |
| Related Party Transactions | None in 2024 | Governance Committee oversees; no transactions reported |
Expertise & Qualifications
- Former CEO of Aon Hewitt and former CIO of Boeing Commercial Airplanes, bringing expertise in HR outsourcing, technology operations, and large-scale global management .
- As I&T Chair, oversees technology strategy, cybersecurity, artificial intelligence, data protection, and major tech investments—aligned with TBI’s digital initiatives and risk oversight framework .
- Independent status, multi-committee service (Compensation and Governance), and experience in professional services strengthen board effectiveness in human capital and governance oversight .
Equity Ownership
| Item | Value |
|---|---|
| Beneficial Ownership (shares) | 61,970 shares |
| Percent of Class | * (Company table indicator) |
| Deferred RSUs | 10,050 RSUs deferred until 90 days after separation from Board |
| Director Ownership Guidelines | 5× base annual cash retainer; includes RSUs and deferred shares; all non-employee directors met or were on track as of 2024 year-end |
| Hedging/Pledging | Hedging prohibited; pledging discouraged per policy |
| Related-Person Exposure | No related person transactions reported for 2024 |
Governance Assessment
- Strengths:
- Independent director with seven years of service; committee breadth including Compensation and Governance, and I&T Committee Chair role focused on cybersecurity/AI oversight .
- Strong attendance culture (≥75% for all directors) and structured board processes (executive sessions, quarterly strategy reviews) support effective oversight .
- Director equity aligned via RSUs; optional deferral indicates long-term alignment; director ownership guidelines set at 5× cash retainer and compliance on track .
- No related-party transactions in 2024; anti-hedging policy reduces misalignment risks .
- Shareholder support evident with 91% say-on-pay approval (signal of governance/compensation credibility) .
- Watch items:
- RSUs are time-based (no disclosed performance metrics for director equity), placing alignment emphasis on ownership/deferral rather than explicit performance hurdles .
- I&T Committee’s broad remit (AI/cyber) centralizes critical risk oversight; continued board education and periodic evaluation improvements noted, but ongoing rigor remains essential given evolving tech risks .